Clascoterone cream was submitted for review to Health Canada in August 2022, with hopes of approval within 3-6 months. It may potentially enhance finasteride's effects for hair loss treatment.
The conversation is about starting a Discord group for people using KX-826 as their only treatment for hair loss, excluding those who are not serious or use multiple treatments. Someone agrees with the idea but mentions "GP :3," which is unclear.
The user is concerned about high LH and estradiol levels after using finasteride but reports no side effects. They are seeking advice on whether these levels are concerning despite feeling fine.
User tries dermapen for hair loss and plans to use non-mainstream topicals like c60, ghk-cu, and ptd-dbm with valproic acid. They also use a head massager and modified LLLT belt for additional treatment.
New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.
The conversation is about obtaining pyrilutamide for hair loss treatment from China through a contact, with details on pricing and shipping. The user offers to facilitate the purchase and shipment for a small commission.
A user shared their experience 7.5 months after receiving 3950 hair grafts at Sule Hair Transplant in Istanbul, Turkey, with positive feedback on the transformation. The discussion included costs, recovery time, and the use of medications like finasteride and minoxidil post-transplant.
The conversation discusses using topical synthetic prostaglandins like Bimatoprost, Latanoprost, and cetirizine for hair growth. The user shares a link suggesting these treatments may be effective.
Topical spironolactone is available in the UK for men to block androgen receptors locally. The user seeks opinions or experiences from others who have used it.
The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.
A 34-year-old male documents his hair growth journey using the iRestore Elite laser cap, biotin, and Pure Synergy Organic Superfood Capsules, after unsuccessful hair transplant and previous treatments with minoxidil and finasteride. Replies suggest using finasteride or dutasteride instead and caution against excessive use of the laser cap.
The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.
Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.
Korean scientists developed a red light therapy that reduces a hair loss marker by 92%. Users discussed the benefits and drawbacks of natural sunlight versus red light caps for hair health, with some suggesting supplements for vitamin D.
PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.
The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.
Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
A Silicon Valley-backed company aims to cure hair loss. Exciting advancements include mRNA therapies, gene editing, hair cloning, AR degraders, anti-androgens, cell-based rejuvenation, and AI-based drug discovery, with hopes for FDA approval of GT20029 within 10 years.
The conversation discusses the potential availability of a new hair loss treatment, GT20029, on the grey market, with users suggesting it could be within a year but advising against using grey market products due to safety concerns and complexity of the drug.
The conversation discusses a patent for using topical resveratrol and melatonin to treat androgenetic alopecia (AGA) and also mentions interest in topical sulforaphane as a treatment.
Capilia Longa is considered as an alternative to Minoxidil for beard growth, with some users reporting positive results. However, concerns exist about its effectiveness and high cost, especially for scalp use.
Shiseido's S-DSC Hair Multiplication Treatment in Japan is available to foreigners but is expensive and not very effective. Despite past disappointments, there is hope for future treatments with more options in development beyond Minoxidil and Finasteride.
The conversation is about sourcing RU58841 for hair loss treatment, with a focus on finding reputable sellers. The user plans to use 10mg/ml daily, split into two doses, prioritizing quality over price.
A user is considering starting spironolactone for androgenetic alopecia but is concerned about stopping it before pregnancy. Another user suggests trying topical treatments as an alternative.
A user tried a Korean hair loss shampoo and treatment set, noting it improved scalp and hair quality but lacked ingredient details. Other users expressed skepticism about its effectiveness, suggesting it might not significantly impact hair loss.
Methylsulfonylmethane (MSM) is not a treatment for male pattern baldness but can accelerate hair growth and thicken miniaturized hairs, with the side effect of increased hair growth all over the body. The user asks others to share their experiences with MSM.
Stem cell-related treatments and drugs like RCGD423 and WAY are being tested for hair growth. Clinics are conducting tests on patients who haven't had previous treatments.